Scienza e Tecnologia
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Operational Highlights
Friday, March 5, 2021
8:30 am ET
(888) 231-8191
(647) 427-7450
(if needed) 569-6653
please click here
A live webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here and will be archived for three months. A dial in replay will be available for one week and can be accessed by dialing (855) 859-2056 ( North America ) or (416) 849-0833 (International) and using reference code: 569-6653.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies of pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.
Chief Financial Officer
+1-403-670-7658
KLook@oncolytics.ca
LifeSci Advisors
+1-917-679-9282
tim@lifesciadvisors.com